Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | SVP, General Counsel | August 21, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 488,267 |
Reported balance
After 2026-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-21 · Sale · Disposed 29,697 · Balance 488,267 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023. F3: Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023.
F3: Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 25, 2026 20:43 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 29,697 | $2.12 | $62,957.64 |
DisclosureSEC source: 0001628280-26-058920 · wk-form4_1787690594.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,267 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023. F3 · balance_after: Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 152,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001362155-26-000002 · wk-form4_1770243135.xml · derivative · entry 3 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,480 Underlying: Common Stock · 152,480 shares Expires not disclosed F4 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 539,072 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001362155-26-000002 · wk-form4_1770243135.xml · derivative · entry 2 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,072 Underlying: Common Stock · 539,072 shares Expires 2036-02-02 F3 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:12 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 22,900 | $1.76 | $40,304.00 |
DisclosureSEC source: 0001362155-26-000002 · wk-form4_1770243135.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,948 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 6,404 | $1.71 | $10,950.84 |
DisclosureSEC source: 0001737287-25-000020 · wk-form4_1738790190.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,848 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 512,370 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001737287-25-000009 · wk-form4_1738113364.xml · derivative · entry 2 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,370 Underlying: Common Stock · 512,370 shares Expires 2035-01-24 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 144,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000009 · wk-form4_1738113364.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 594,252 Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:15 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 28,310 | $2.79 | $78,843.35 |
DisclosureSEC source: 0001593968-24-001096 · primary_01.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,324 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 22:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 147,778 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001593968-24-000196 · primary_01.xml · derivative · entry 2 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,778 Underlying: Common Stock · 147,778 shares Expires 2034-01-25 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 22:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 41,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000196 · primary_01.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,634 Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 22:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 960,854 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001593968-23-001226 · primary_01.xml · derivative · entry 3 Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960,854 Underlying: Common Stock · 960,854 shares Expires 2033-08-14 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 22:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 326,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001226 · primary_01.xml · nonDerivative · entry 2 Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,834 Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 22:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 108,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001226 · primary_01.xml · nonDerivative · entry 1 Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,958 F1 · shares: Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.